EXPERIMENTAL CELL RESEARCH is a highly respected journal published by Elsevier Inc, specializing in the dynamic and ever-evolving field of Cell Biology. With an impact factor positioned in the Q2 quartile for 2023, it ranks at the 124th position out of 285 in the Scopus Ranks, indicating a solid reputation among peers in the domains of biochemistry, genetics, and molecular biology. Since its inception in 1950, the journal has contributed significantly to the dissemination of groundbreaking research, providing a platform for studies that explore the nuances of cellular mechanisms, processes, and experimental methodologies. Although the journal currently does not offer open access, its commitment to high-quality, peer-reviewed research continues to attract submissions from leading scientists and scholars across the globe. Researchers, professionals, and students alike will find this journal an invaluable resource for keeping abreast of current developments and innovative breakthroughs in cellular science.

SEMINARS IN CANCER BIOLOGY is a leading journal dedicated to the dissemination of groundbreaking research in the field of cancer biology. Published by Academic Press Ltd - Elsevier Science Ltd, this esteemed journal plays a pivotal role in the academic community, boasting a prestigious impact factor and ranking within the Q1 category in Cancer Research for 2023. With an exceptional Scopus rank of #11 out of 230 in the realms of Biochemistry, Genetics, and Molecular Biology, it holds a significance that underscores its influence in advancing the understanding of cancer mechanisms and therapies. Established in 1990, the journal fosters a comprehensive platform for sharing high-quality and innovative research, critical reviews, and expert opinions aimed at professionals and researchers in the field. While not an open-access journal, it provides valuable insights that enhance the collective knowledge essential for the fight against cancer. For researchers, clinicians, and students, SEMINARS IN CANCER BIOLOGY is a crucial resource, paving the way for new discoveries and innovations in cancer treatment and prevention.

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

OncoTargets and Therapy is a prestigious, peer-reviewed journal dedicated to the rapid dissemination of research in the fields of oncology and pharmacology. Published by DOVE MEDICAL PRESS LTD in New Zealand since 2008, this journal has embraced the open access model, ensuring that critical cancer-related research is freely accessible to a global audience. With an impressive impact factor reflected by its Q2 ranking in both the Oncology and Pharmacology (medical) categories for 2023, as well as Scopus rankings placing it in the top 91st percentile in pharmacology and the 84th percentile in oncology, OncoTargets and Therapy stands out as a vital resource for researchers, clinicians, and students alike. The journal focuses on therapeutics, novel drug discoveries, and clinical trials, encouraging collaborative efforts to combat cancer effectively. By providing a platform for groundbreaking studies and comprehensive reviews, it plays a crucial role in advancing knowledge and practice in these critical areas of medical science.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

Animal Cells and Systems, published by TAYLOR & FRANCIS LTD, is a prominent open-access journal that has been disseminating high-quality research since 2017. With an ISSN of 1976-8354 and an E-ISSN of 2151-2485, this journal is dedicated to advancing the understanding of animal cellular biology and the intricate systems that govern organismal functions. Recognized for its rigorous peer-review process, it holds an esteemed position in the academic community, boasting a Q1 ranking in Animal Science and Zoology and a Q2 ranking in Biochemistry, Genetics and Molecular Biology for 2023. The journal is indexed in Scopus, ranked #79/490 in Animal Science and Zoology and #85/221 in General Biochemistry, Genetics, and Molecular Biology, affirming its impact and relevance in these fields. With a commitment to providing researchers, professionals, and students with vital insights and cutting-edge research, Animal Cells and Systems is an essential resource for those looking to explore the complex landscapes of animal biology.

DRUG RESISTANCE UPDATES is a premier academic journal published by Churchill Livingstone, focusing on the critical areas of drug resistance in various diseases including cancer, infectious diseases, and the pharmacological challenges associated with these conditions. With a robust impact factor and a prestigious Q1 ranking across multiple categories such as Cancer Research, Infectious Diseases, and Pharmacology, this journal is recognized for its significant contributions to the field. Since its inception in 1998 and continuing through to 2024, it has become an essential resource for researchers, clinicians, and policy-makers aiming to understand and combat the evolving challenges of drug resistance. Although it is not an open-access publication, it provides vital insights and research findings that are pivotal in influencing treatment strategies and advancing knowledge within the scientific community. For stellar insights backed by rigorous peer review, DRUG RESISTANCE UPDATES should be on the radar of every professional concerned with the intricacies of modern medicine and pharmacology.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.